%0 Journal Article
%T Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients
%A G. Huygh
%A Paul M. J. Clement
%A H. Dumez
%A P. Sch ffski
%A H. Wildiers
%A J. Selleslach
%A J. M. Jimeno
%A I. De Wever
%A R. Sciot
%A L. Duck
%A A. T. Van Oosterom
%J Sarcoma
%D 2006
%I Hindawi Publishing Corporation
%R 10.1155/srcm/2006/56282
%X Purpose. To evaluate the activity and safety of ecteinascidin (ET-743) in pretreated patients with advanced or metastatic soft tissue and bone sarcoma. Patients or subjects. Eighty-nine patients received ET-743 as a 24-hour continuous infusion at a dose of 900–1500 μg/m2 every 3 weeks. Results. We observed one complete remission, 5 partial remissions, one minimal response, and 16 patients with a disease stabilization of 6 months or more. The objective response rate was 6.7% and the clinical benefit rate at 3 and 6 months was 37.7% and 23.4%, respectively. Responses were noted in patients with lipo-, leiomyo-, osteo-, and myogenic sarcoma, with a median duration of 9.85 months. Toxicity mainly involved an asymptomatic elevation of transaminases and neutropenia. Estimated 1- and 2-year survival rates were 39.4% and 15.8%. Median overall survival was 8.25 months. Discussion. This retrospective analysis confirms that ET-743 induces objective responses and progression arrest in a clinically relevant proportion of patients.
%U http://www.hindawi.com/journals/srcm/2006/056282/abs/